Purpose Of Review: Calcific aortic stenosis (CAVS) is the most common form of valvular heart disease in developed countries, increasing in prevalence with the aging population. Surgical or transcatheter aortic valve replacement is the only treatment available for CAVS. However, these interventions are typically reserved for severe symptomatic aortic stenosis (AS). The purpose of this review is to summarize the recent literature in uncovering the underlying pathophysiology of CAVS in the setting of lipoprotein (a) [Lp(a)] and emerging therapies targeting Lp(a) which may help halt disease progression in CAVS.
Recent Findings: Pathophysiologic, epidemiological, and genetic studies over the past two decades have provided strong evidence that Lp(a) is an important mediator of calcific aortic valvular disease (CAVD). Studies suggest that Lp(a) is a key carrier of pro-calcifying oxidized phospholipids (OxPL). The metabolism of OxPL results in a pro-inflammatory state and subsequent valvular thickening and mineralization through pro-osteogenic signaling. The identification of Lp(a) as a causal mediator of CAVD has allowed for opportunities for emerging therapeutic agents which may slow the progression of CAVD (Fig. 1JOURNAL/cocar/04.03/00001573-202109000-00007/figure1/v/2021-08-04T080204Z/r/image-jpeg).
Summary: This review summarizes the current knowledge on the association of Lp(a) with CAVD and ongoing studies of potential Lp(a)-lowering therapies. Based on the rate-limiting and causal role of Lp(a) in progression of CAVS, these therapies may represent novel pharmacotherapies in AS and inform the developing role of Lp(a) in the clinical management of CAVD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934151 | PMC |
| http://dx.doi.org/10.1097/HCO.0000000000000901 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk factors and predictive model for moderate to severe perivalvular leakage following transcatheter aortic valve replacement.
Am J Transl Res
December 2024
Department of Cardiac Surgery, The Second Hospital of Hebei Medical University Shijiazhuang 050000, Hebei, China.
Objective: To identify the risk factors associated with moderate to severe perivalvular leakage (PVL) after transcatheter aortic valve replacement (TAVR) and to construct a prediction model for this risk.
Methods: A retrospective analysis was conducted on 128 patients with severe aortic stenosis who had received TAVR in The Second Hospital of Hebei Medical University from January 2019 to January 2024. The length of the aortic regurgitation bundle and annular circumference ratio were measured by transesophageal echocardiography immediately after the valve implantation.
Association of the abdominal aortic calcification with all-cause and cardiovascular disease-specific mortality: Prospective cohort study.
PLoS One
January 2025
Department of Vascular Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Background: Abdominal aortic calcification (AAC) is a prevalent form of vascular calcification associated with adverse cardiovascular outcomes. While previous studies on AAC and cardiovascular risk exist, many have limitations such as small sample sizes and limited clinical significance outcomes. This study aims to prospectively investigate the association between AAC and all-cause and cardiovascular disease (CVD)-specific mortality rates in a nationally representative sample of adults in the United States, using data from the National Health and Nutrition Examination Survey (NHANES).
View Article and Find Full Text PDFCoexisting Calcific Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Real-World Evaluation of Clinical Characteristics and Outcomes.
J Am Heart Assoc
January 2025
Pfizer Inc New York NY USA.
Background: The coexistence of transthyretin cardiac amyloidosis (ATTR-CA) and aortic stenosis (AS) is increasingly recognized, but the clinical consequences are unclear. We aimed to characterize clinical outcomes in AS plus ATTR-CA compared with only AS or ATTR-CA.
Methods And Results: In a retrospective cohort study, patients with AS only, ATTR-CA only, or AS plus ATTR-CA were identified using all-payer claims data (2015-2021).
Association of aortic valve size with the degree of aortic valve calcification in severe high-gradient aortic stenosis.
Eur Heart J Cardiovasc Imaging
January 2025
Karl Landsteiner University of Health Sciences, Krems, Austria.
Aims: Less pronounced calcification of the aortic valve (AVC) was observed in women with aortic stenosis (AS) as compared to men. Since women have smaller aortic valves (AV), this could explain a lower calcium load. We aimed to analyze the association of AV size with AVC independent from sex.
View Article and Find Full Text PDFAdjustment of the Framingham index by abdominal aortic calcification scores enables a more accurate prediction of long-term cardiac events in general population aged 40 years and above: evidence from NHANES 2013-2014.
BMC Public Health
January 2025
Department of Medical Ultrasonics, First Affiliated Hospital of Medical College, Xi'an Jiao tong University, No.277 Yanta West Road, Xi'an, 710061, Shaanxi, China.
Background: Abdominal aortic calcification (AAC) is considered as a strong predictor of cardiovascular disease (CVD) events. Our study aimed to investigate whether the predicted risk for cardiac death with the Framingham risk score (FRS) could be further improved with the addition of AAC score in general population aged ≥ 40 years.
Methods: A total of 2971 participants aged ≥ 40 years in the National Health and Nutrition Examination Surveys (NHANES) 2013-2014 were followed up.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!